PharmAthene to Host Second Quarter 2008 Conference Call and Webcast on Tuesday, August...

PharmAthene to Host Second Quarter 2008 Conference Call and Webcast on
Tuesday, August 12, 2008

ANNAPOLIS, Md., Aug. 5 /PRNewswire-FirstCall/ -- PharmAthene, Inc.
(Amex: PIP) a biodefense company developing medical countermeasures against
biological and chemical threats, announced today that its financial results
for the second quarter of 2008 will be released on Tuesday, August 12, 2008.
PharmAthene management will be hosting a conference call to discuss its
second quarter 2008 financial results. The call is scheduled to begin at 4:30
p.m. Eastern Time on Tuesday, August 12, 2008 and will last approximately 45
minutes.
The dial-in number within the United States is 800-706-7741. The dial-in
number for international callers is 617-614-3471. The participant passcode is
48062719.
A replay of the conference call will be available for 30 days, beginning
at approximately 6:30 p.m. Eastern Time on August 12, 2008 until approximately
11:50 p.m. Eastern TimeSeptember 9, 2008. The dial-in number from within the
United States is 888-286-8010. For international callers, the dial-in number
is 617-801-6888. The participant passcode is 76313724.
The conference call will also be webcast and can be accessed from the
company's website at www.pharmathene.com. A link to the webcast may be found
under the Investor Relations section of the website. The webcast will be
available for 30 days, or until approximately September 9, 2008.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and
its allies by developing and commercializing medical countermeasures against
biological and chemical weapons. PharmAthene's lead product development
programs include (1) SparVax(TM) -- a second generation recombinant protective
antigen (rPA) anthrax vaccine, (2) Valortim(TM) -- a fully human monoclonal
antibody for the prevention and treatment of anthrax infection, (3)
Protexia(R) -- a novel bioscavenger for the prevention and treatment of
morbidity and mortality associated with exposure to chemical nerve agents, (4)
RypVax(TM) -- a recombinant dual antigen vaccine for plague, and (5) a third
generation rPA anthrax vaccine. For more information about PharmAthene, please
visit www.PharmAthene.com.
SOURCE PharmAthene, Inc.

Stacey Jurchison for PharmAthene, Inc., +1-410-269-2610,
JurchisonS@PharmAthene.com